Melane Sampson, Author at BioTuesdays

Uncategorized

CERo reveals updates to Phase 1 trial of CER-1236 in AML

CERo Therapeutics (OTCQB: CERO) has announced advancements to the CertainT-1 trial focused on patients with acute myeloid leukemia (AML). According to CERo, following completion of the dose-limiting toxicity (DLT)...

December 17, 2025

Developments

FDA grants fast track designation for Adagene’s muzastotug

Adagene (NASDAQ: ADAG) has announced that the FDA has designated muzastotug, in combination with Merck’s (NYSE: MRK) anti-PD-1 therapy, KEYTRUDA (pembrolizumab), as a fast track product for adult patients with...

December 16, 2025

Executive Moves

Brooke Story joins PolyPid as chair of the BOD

PolyPid (NASDAQ: PYPD) has announced the appointment of medtech leader Brooke Story as chair of the board of directors (BOD), effective December 11, 2025. Ms. Story brings more than 25 years of leadership experience in...

December 16, 2025

Feature

Aqua Medical reversing the metabolic clock with innovative vapor ablation technology

Closely held Aqua Medical is advancing therapy for gastrointestinal (GI) and metabolic diseases—including Type 2 diabetes—using its disruptive, transoral, outpatient vapor-based endoscopic ablation platform.

December 16, 2025

Executive Moves

ENvue appoints David Johnson as chairman

ENvue Medical (NASDAQ: FEED) announced the appointment of David Johnson as chairman of the board. Mr. Johnson is a seasoned healthcare executive and board leader with more than 30 years of experience across the medical...

December 15, 2025

Developments

RedHill’s positive opaganib results indicate reduction in venetoclax resistant cells

RedHill Biopharma (NASDAQ: RDHL) has announced positive in vivo results that indicate opaganib combined with venetoclax reduces chronic lymphocytic leukemia (CLL) cells by half compared to controls—demonstrating...

December 15, 2025

Developments

Kyverna announces positive data from trial of miv-cel in SPS

Kyverna Therapeutics (NASDAQ: KYTX) has announced positive topline data from KYSA-8, its registrational Phase 2 trial of mivocabtagene autoleucel (miv-cel)—a fully human, autologous CD19-targeting CAR T-cell therapy...

December 15, 2025

Developments

Cadrenal acquires VLX-1005 for patients with HIT

Cadrenal Therapeutics (NASDAQ: CVKD) has announced the acquisition of VLX-1005—a first-in-class, Phase 2 12-LOX inhibitor—along with additional 12-lipoxygenase (12-LOX) assets from closely held Veralox Therapeutics, for...

December 11, 2025

Developments

Xtant launches next-gen nanOss Strata synthetic bone graft

Xtant Medical (NYSE American: XTNT) has announced the commercial launch of its next-generation innovative synthetic bone graft in the nanOss line, Strata. According to Xtant, the nanocrystalline structure of...

December 11, 2025

Developments

AC Immune reports positive interim data of a-syn active immunotherapy in early PD

AC Immune (NASDAQ: ACIU) has announced positive interim safety and efficacy results from the Phase 2 VacSYn trial of its wholly-owned anti-alpha-synuclein (a-syn) active immunotherapy, ACI-7104.056, in early Parkinson’s...

December 11, 2025

Author - Melane Sampson

CERo reveals updates to Phase 1 trial of CER-1236 in AML

FDA grants fast track designation for Adagene’s muzastotug

Brooke Story joins PolyPid as chair of the BOD

Aqua Medical reversing the metabolic clock with innovative vapor ablation technology

ENvue appoints David Johnson as chairman

RedHill’s positive opaganib results indicate reduction in venetoclax resistant cells

Kyverna announces positive data from trial of miv-cel in SPS

Cadrenal acquires VLX-1005 for patients with HIT

Xtant launches next-gen nanOss Strata synthetic bone graft

AC Immune reports positive interim data of a-syn active immunotherapy in early PD

Subscribe